Integra LifeSciences Expands Accell Evo3 Product Line

PLAINSBORO, N.J., Sep 29, 2009 (GlobeNewswire via COMTEX News Network) — Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today the release of a smaller configuration of the innovative Accell Evo3(R) Demineralized Bone Matrix. Originally introduced as a bone void filler for large orthopedic reconstructive procedures, the new smaller size of Accell Evo3(R) expands the possible application options for the surgeon, particularly in procedures where smaller amounts of demineralized bone matrix are required.

Accell Evo3(R) is an advanced demineralized bone matrix graft material that is composed of the proprietary Accell(R) Bone Matrix, an optimized blend of particulate Demineralized Bone Matrix (DBM), and a unique poloxamer Reverse Phase Medium. The Reverse Phase Medium is a thermo-reversible carrier that thickens at body temperature and is more flowable at room temperature. The carrier imparts exceptional handling and graft containment characteristics for Integra’s DBM based products.

The optimized platform of Accell Evo3(R) enables the bone healing process to take advantage of the naturally available bone proteins found in Accell(R) Bone Matrix and DBM. Accell Evo3(R) has been specifically formulated to provide surgeons with excellent intraoperative handling characteristics for proper utilization of the graft material, and is marketed in combination with a new custom designed open bore syringe for easy delivery of the matrix into the operative field.

Bone grafts provide a foundation or scaffold for the patient’s body to grow new bone, and can stimulate new bone production and bone fusion. Accell Evo3(R) may be used as a bone graft extender in the spine, extremities and pelvis or as a bone void filler for the extremities and pelvis, and may replace the need to harvest bone graft material from the iliac crest, thus sparing the patient additional surgery and postoperative pain.

“Integra OrthoBiologics is dedicated to advancing patient care by providing the surgeon with a wide range of innovative and high quality bone graft substitutes. We are pleased to provide the advanced Accell Evo3(R) technology in a new configuration to better accommodate the needs of surgeons and their patients,” said Bill Weber, Vice President of Integra OrthoBiologics.

The U.S. market size for bone graft substitutes in orthopedic spinal procedures is estimated at $1.4 billion. In 2008, an estimated 880,000 orthopedic procedures were performed in the United States, including over 500,000 spinal fusions. Additional applications are found in orthopedic trauma and reconstructive procedures.

Josh Sandberg

Josh Sandberg is the President of Ortho Spine Partners and Partner for The De Angelis Group. He also serves as Co-Founder and Editor of OrthoSpineNews.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button